

Effective from Session: 2016-17										
Course Code	MPH101T	Title of the Course	itle of the Course Modern Pharmaceutical Analytical Techniques I				C			
Year	Ι	Semester	Ι							
Pre-Requisite	B Pharm	Co-requisite	Knowledge of chemical structures of Pharmaceutical	4	0	0	4			
Tre-Kequisite	DThaim	Co-requisite	substances							
	After completion of course student is able to know about									
Course	1.Chemicals and Excipie	ents								
Objectives	2. The analysis of various	s drugs in single and cor	nbination dosage forms							
	3. Theoretical and practical skills of the instruments									
		~								

	Course Outcomes
CO1	Investigate the pharmaceutical substance by absorption and emission techniques.
CO2	Appraise the pharmaceutical substance by nuclear magnetic spectroscopy techniques.
CO3	Examine the mass spectroscopy involved for the pharmaceutical substances.
CO4	Recognize the principle, instrumentation and applications of chromatographic techniques.
CO5	Sketch the principle, instrumentation and applications of electrophoresis and x ray crystallography.
CO6	Apprehend the fundamentals of immunological assays.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	UV-Visible spectroscopy, IR spectroflourimetry , Flame emission spectroscopy and Atomic absorption spectroscopy	<ul> <li>a. UV-Visible spectroscopy: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy, Difference/ Derivative spectroscopy.</li> <li>b. IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier -Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy.</li> <li>c. Spectroflourimetry: Theory of Fluorescence, Factors affecting fluorescence, Quenchers, Instrumentation and Applications of fluorescence spectrophotometer.</li> <li>d. Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation, Interferences and Applications.</li> </ul>	11	1
2	NMR spectroscopy	NMR spectroscopy: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT-NMR and 13C NMR. Applications of NMR spectroscopy.	11	2
3	Mass Spectroscopy	Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy.	11	3
4	Chromatography	11	4	
5	Electrophoresis and X-ray Crystallography	<ul> <li>g) Affinity chromatography</li> <li>a. Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following:</li> <li>a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing</li> <li>b. X ray Crystallography: Production of X rays, Different X ray diffraction methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.</li> </ul>	11	5
6	Immunological assays	Immunological assays: RIA (Radio immuno assay), ELISA, Bioluminescence assays	5	6
Referen	ice Books:			
1. Spe	ectrometric Identification	n of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.		
2. Pri	nciples of Instrumental A	Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Ban	galore, 1998	
3. Ins	trumental methods of an	alysis – Willards, 7th edition, CBS publishers.		
4. Pra	actical Pharmaceutical Cl	hemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.		
5. Org	ganic Spectroscopy - Wi	lliam Kemp, 3rd edition, ELBS, 1991.		
		rugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.		
7. Pha	armaceutical Analysis - 1	Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series		

#### e-Learning Source:

https://www.classcentral.com/course/swayam-spectroscopic-techniques-for-pharmaceutical-and-biopharmaceutical-industries-14301

https://www.sciencedirect.com/science/article/pii/S1878535213001056

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258797/

https://www.google.co.in/books/edition/Pharmaceutical\_Analysis/Ub8wod1CJ50C?hl=en&gbpv=1&dq=pharmaceutical+analysis+spectral+chromatog raphy&printsec=frontcover

 $\label{eq:https://www.google.co.in/books/edition/Pharmaceutical_Analysis_E_Book/YExgDAAAQBAJ?hl=en&gbpv=1&dq=pharmaceutical+analysis+spectral+chromatography&printsec=frontcover$ 

	Course Articulation Matrix: (Mapping of COs with POs and PSOs)																	
PO- PSO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO1	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-
CO2	3	3	3	2	3	3	2	3	3	3	3	-	3	3	3	-	-	-
CO3	3	3	3	2	3	3	2	2	3	2	3	-	3	3	3	-	-	-
CO4	3	3	3	3	3	2	2	2	3	3	3	-	3	3	3	-	-	-
CO5	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-
CO6	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-

1-

Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator	
	Sign & Seal of HoD



Effective from Session: 2016-2017											
Course Code	MPH102T	Title of the Course         Drug delivery systems         I			Т	P	С				
Year	Ι	Semester	Ι	4	0	0	4				
Pre-Requisite	B Pharm	Co-requisite			U	U	4				
1. The various approaches for development of novel drug delivery systems.											
Course Objectives	<ol> <li>The criterial for selection of drugs and polymers for the development of the delivering system.</li> <li>The formulation and evaluation of novel drug delivery system.</li> </ol>										

	Course Outcomes								
CO1	Explain drug delivery systems which give detailed information on transporting a pharmaceutical								
	compound in the body as needed to safely achieve its desired therapeutic effect. Also about the								
	approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the								
	body as needed to safely achieve its desired therapeutic effect with suitable drug delivery.								
CO2	Know vaccine delivery and different mode of application approaches for clinical use.								
CO3	Ability to communicate different types of Drug carrier used in the process of drug delivery which serves to								
	improve the selectivity, effectiveness, and/or safety of drug administration.								
CO4	Apply latest drug delivery knowledge and think to develop new formulation based on the individual								
	requirement.								
CO5	Create recent developments in protein and peptide for parenteral delivery approaches will give new								
	dimension of drug deliver for antibiotics, insulin, etc.								

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Sustained Release(SR) and Controlled Release (CR) formulations:	Introduction and basic concepts, advantages, disadvantages Factors influencing, Physicochemical and biological approaches for SR/CR formulation Mechanism of drug delivery from SR/CR formulation Polymers introduction, definition, classification, properties Application Dosage forms for personalized medicine: introduction, definition, pharmacogenetics Categories of patients for personalized medicines: customized drug delivery systems Bioelectronic medicines 3D printing of pharmaceuticals, telepharmacy	12	1
2	Rate controlled drug delivery systems	Rate controlled drug delivery systems: principles and fundamentals, types Activation: Modulated drug delivery systems; mechanically activated, pH activated Enzyme activated, osmotic activated drug delivery systems Feedback regulated drug delivery systems; principles and fundamentals Revision Compartment models Pharmacokinetic study	12	3
3	Gastro-retentive dds	Principle, concepts advantages and disadvantages Modulation of GI transit time approaches to extend GI transit Buccal dds; principle of mucoadhesion, advantages and disadvantages Mechanism of drug permeation, methods of formulations and its evaluation	12	4
4	Ocular and Buccal dds	Ocular, Buccal DDS an introduction, advantages, disadvantages, barriers of drug permeation, methods to overcome barriers.	12	5

	Transdermal dds,	structure of skin and barriers		
		Penetration enhancers		
		Formulation and evaluation		
	Protein and peptide	Barriers for protein delivery		
	delivery	Formulation and evaluation		
5	Vaccine delivery	Vaccines uptake of antigens	12	2
	system	Single short vaccines		
	system	Mucosal and transdermal delivery of vaccines		
Referen	ice Books:			
1. Y W	V. Chien, Novel Drug Del	ivery Systems, 2nd edition, revised and expanded, Marcel Dekker, Inc., N	lew York,	1 992.
2. Rob	oinson, J. R., Lee V. H. L,	Controlled Drug Delivery Systems, Marcel Dekker, Inc., New York, 1992	2.	
3. Enc	vclopaedia of controlled	delivery, Editor- Edith Mathiowitz, Published by WileyInterscience Public	cation, Joh	n Wiley
	ons, Inc, New York! Chic		,	j
		vel Drug Delivery, CBS Publishers & Distributors, New Delhi, First edition	on 1997 (r	eprint in
2001)				- I
/		trolled Drug Delivery - concepts and advances, Vallabh Prakashan, New I	Delhi, First	edition
2002	5	<b>5 5 1 , , , , , , , , , , , , , , , , , , ,</b>	,	
JOUR	NALS			
1. Indi	an Journal of Pharmaceu	tical Sciences (IPA)		
2. Indi	an drugs (IDMA)			
3.Jouri	nal of controlled release (	(Elsevier Sciences) desirable		
4. Dru	g Development and Indu	strial Pharmacy (Marcel & Decker) desirable		
e learn	ning sources			
		les/s41551-021-00698-w		

		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO-PS O CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO1	3	3	1	3	1	1	1	2	1	1	1	-	3	3	3	-	-	-
CO2	3	3	-	1	1	1	-	2	1	1	1	-	3	3	3	-	-	-
CO3	3	3	-	2	1	-	-	2	1	1	1	-	3	3	3	-	-	-
CO4	3	3	1	2	1	1	1	2	1	1	1	-	3	3	3	-	-	-
CO5	3	2	1	3	1	1	1	3	1	1	1	-	3	3	3	-	-	-

1-

Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator	
	Sign & Seal of HoD



Effective from Session: 2016-2017										
Course Code	MPH103T	103TTitle of the CourseModern PharmaceuticsLTPC								
Year	Ι	Semester	Ι	4			4			
Pre-Requisite	B Pharm	Co-requisite	74	-	-	4				
Course Objectives	2.The Active 3. Industrial M 4.Optimization	Management and GMP ( on Techniques & Pilot P	ents and Generic drug Product development							

	Course Outcomes
CO1	Apply the concepts of preformulation and optimization techniques during formulation development.
CO2	Recognize the importance of validation of methods, equipments and processes during pharmaceutical manufacturing.
CO3	Describe current good manufacturing practices guidelines and industrial management.
CO4	Analyze the importance of tablet compression and compaction studies.
CO5	Understand different consolidation parameters employed in formulation development and evaluation.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Preformulatio n concepts and optimization techniques	Preformation Concepts– Drug Excipient interactions -different methods, kinetics of stability, Stability testing. Theories of dispersion and pharmaceutical Dispersion (Emulsion and Suspension, SMEDDS) preparation and stability large and small volume parental – physiological and formulation consideration, Manufacturing and evaluation. Optimization techniques in Pharmaceutical Formulation- Concept and parameters of optimization, Optimization techniques in pharmaceutical formulation and processing. Statistical design, Response surface method, Contour designs, Factorial designs and application in formulation	20	1
2	Validation	Introduction to Pharmaceutical Validation, Scope & merits of Validation, Validation and calibration of Master plan, ICH & WHO guidelines for calibration and validation of equipments, Validation of specific dosage form, Types of validation. Government regulation, Manufacturing Process Model, URS, DQ, IQ, OQ & P.Q. of facilities	10	2
3	cGMP and Industrial Management	Objectives and policies of current good manufacturing practices, layout of buildings, services, equipments and their maintenance Production management: Production organization, materials management, handling and transportation, inventory management and control, production and planning control, Sales forecasting, budget and cost control, industrial and personal relationship. Concept of Total Quality Management	10	3
4	Compression and compaction	Physics of tablet compression, compression, consolidation, effect of friction, distribution of forces, compaction profiles. Solubility	10	4
5	Study of consolidation parameters:	Diffusion parameters, Dissolution parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2 and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard deviation, Chi square test, students T-test, ANOVA test	10	5
Referen	ce Books:			
<ol> <li>2. Pharm</li> <li>3. Mode</li> </ol>	naceutical Dosage f	ndustrial Pharmacy by Lachmann and Libermann Forms: Parenteral medications Vol. 1-2; By Leon Lachmann. By Gillbert and S. Banker.		

Remington's Pharmaceutical Sciences.
 Physical Pharmacy; By Alfred martin
 Pharmaceutical Dosage Form: Tablets Vol. 1-3 by Leon Lachmann.

### e-Learning Source:

. https://www.taylorfrancis.com/books/edit/10.1201/9780824744694/modern-pharmaceutics-gilbert-banker-juergen-siepmann-christopher-rhodes

				Сог	irse Ar	ticulati	on Mat	rix: (M	apping o	f COs w	ith POs	and PSOs	)					
PO-P SO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
C01	3	3	3	3	2	3	3	3	3	2	3	-	3	3	3	-	-	-
CO2	3	3	3	2	2	3	3	3	3	3	3	-	3	3	3	-	-	-
CO3	3	3	3	2	3	3	3	3	3	3	3	-	3	3	3	-	-	-
CO4	3	3	3	2	2	3	2	3	3	3	3	-	3	3	3	-	-	-
CO5	3	3	3	3	3	3	3	3	3	2	3	-	3	3	3	-	-	-

Name & Sign of Program Coordinator

Sign & Seal of HoD



Effective from Session: 201	Effective from Session: 2016-2017											
Course Code	MPH-104T	Title of the Course	Regulatory Affairs	L	Т	Р	С					
Year	Ι	Semester	Ι		0	0						
Pre-Requisite	B Pharm	Co-requisite	-	4	0	0	4					
Course Objectives	<ol> <li>The Regul</li> <li>Preparation</li> <li>Post approvide the second second</li></ol>	atory guidance's and gu of Dossiers and their so val regulatory requirement of global documents in als requirements for app	heric drugs, drug development process idelines for filing and approval process ubmission to regulatory agencies in different countries ents for actives and drug product CTD/ eCTD formats rovals for conducting clinical trial monitoring in clinical trials.									

<b>Course Outc</b>	omes
--------------------	------

CO1	Understand the concepts of innovator and generic drugs, drug development process, regulatory guidance's and guidelines for filing and
	approval process.
CO2	Know the preparation of dossiers and their submission to regulatory agencies in different countries
CO3	Knowledge on post approval regulatory requirements for actives and drug products, submission of global documents in CTD/ eCTD formats.
CO4	Know the Regulatory guidance's and guidelines for filing and approval process in different countries.
CO5	Understand the clinical trials requirements for approvals for conducting clinical trials, pharmacovigilance and process of monitoring in clinical
	trials

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO					
1	a. Documentation in Pharmaceutical Industry	a. Documentation in Pharmaceutical Industry: Master formula record, DMF (Drug Master File), distribution records. Generic drugs product development Introduction, Hatch-Waxman act and amendments, CFR (CODE OF FEDERAL REGULATION), drug product performance, in-vitro, ANDA regulatory approval process, NDA approval process, BE and	12	1, 2					
	b. Regulatory Requirement for Product Approval:	<ul><li>drug product assessment, in-vivo, scale up process approval changes, post marketing surveillance, outsourcing BA and BE to CRO.</li><li>b. API, biologics, novel, therapies obtaining NDA, ANDA for generic drugs ways and means of US registration for foreign drugs.</li></ul>							
2	Regulatory requirements in different countries	irements in rent countriesdevices. CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory requirements of EU, MHRA, TGA and ROW countries.							
3	Non-Clinical DrugDevelopment	Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier (IMPD) and investigator brochure (IB).	12	4					
4	Clinical Trials	Developing clinical trial protocols. Institutional review board/ independent ethics committee Formulation and working procedures informed Consent process and procedures. HIPAA-							
Referen	ce Books:								
1. G	eneric Drug Product De	velopment, Solid Oral Dosage Forms by Leon Shargel and Isader Kaufer, Marcel Dekker series,	Vol.143.						
	The Pharmaceutical Regroution Regroution (Network) The Pharma Regroup (Network) (Netwo	ulatory Process, Second Edition Edited by Ira R. Berry and Robert P. Martin, Drugs and the Phar are Publishers.	maceutical S	sciences,					
	lew Drug Approval Proc ciences, Vol. 190.	ess: Accelerating Global Registrations by Richard A Guarino, MD,5th edition, Drugs and the Ph	armaceutical	1					
e-Lear	rning Source:								
<u>https</u>	://www.sciencedir	ect.com/topics/medicine-and-dentistry/regulatory-affairs							

		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO- PSO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
C0 C01	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO2	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO3	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-

CO4	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO5	3	2	2	2	2	3	2	1	2	3	3	I	3	2	3	-	-	-

1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation[

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2010	6-17						
Course Code	MPH105P	Title of the Course	Pharmaceutics Practical-I	L	Т	Р	C
Year	Ι	Semester	Ι	-	-	12	-
Pre-Requisite	B. Pharm	Co-requisite	-				
Course Objectives	2. The crite	erial for selection of dru	elopment of novel drug delivery systems gs and polymers for the development of delivering system. of Novel drug delivery systems.				

	Course Outcomes
CO1	Analyze the pharmacopoeial compounds and their formulations.
CO2	Execute the quantitative & qualitative analysis.
CO3	Interpret the results of spectral and chromatographical techniques.
CO4	Analyze preformulation and consolidation parameters during formulation development.
CO5	Evaluate the effects of different factors on disintegration and dissolution profiles of tablets.
CO6	Solve the issues related to formulation and evaluation of novel drug delivery systems.

Experim ent No.	Title of the Experiment	Content of Unit	Contact Hrs.	Mapped CO
	Compound analysisby UV-Visible spectrophoto	Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer. Simultaneous estimation of multi component containing formulations by UV Spectrophotometer.	12	1
1	metry HPLC	Experiments based on HPLC.	12	3
	Gas Chromatogra phy	Experiments based on Gas Chromatography.	12	3
2	Fluorimetry	Estimation of riboflavin/quinine sulphate by fluorimetry.	12	2,4
3	Flame photometry	Estimation of sodium/potassium by flame photometry	12	2,4
	In-vitro	To perform In-vitro dissolution profile of CR/ SR marketed formulation.	12	
4	dissolution	To study the effect of particle size on dissolution of a tablet.	12	5
	study	To study the effect of binders on dissolution of a tablet.	12	
		Formulation and evaluation of sustained release matrix tablets.	12	
	Formulation and	Formulation and evaluation osmotically controlled DDS.	12	
5	evaluation of	Preparation and evaluation of Floating DDS- hydro dynamically balanced DDS	12	4,5
	modified tablets	Formulation and evaluation of Muco adhesive tablets.	12	
	tablets	To study the effect of compressional force on tablets disintegration time.	12	
6	Pre-formulati	To carry out preformulation studies of tablets.	12	2
6	on study	To study Micromeritic properties of powders and granulation.	12	3
7	Trans-dermal patches	Formulation and evaluation of trans dermal patches.	12	5
8	Pharmacokin etic study	To plot Heckal plot, Higuchi and peppas plot and determine similarity factors.	12	3

#### **Reference Books:**

Practical Pharmaceutical Chemistry - Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997. Encyclopedia of controlled delivery, Editor– Edith Mathiowitz, Published by WileyInterscience Publication, John Wiley and Sons, Inc, New York! Chichester/Weinheim

e-Learning Source:

https://www.google.co.in/books/edition/INSTRUMENTAL\_METHODS\_OF\_ANALYSIS\_LAB\_MAN/yOMdEAAAQBAJ?hl=en&gbpv=1 &dg=Pharmaceutical+analysis+practical+manual&printsec=frontcover

https://www.google.co.in/books/edition/Pharmaceutical\_Manufacturing\_Handbook/4c0Hp3AOi8UC?hl=en&gbpv=1&dq=Pharmaceutical +formulation+and+evaluation+practical+manual&printsec=frontcover



		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO-P SO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO1 1	PO1 2	PSO 1	PSO 2	PSO 3	PSO 4	PS O5	PS O6
CO1	3	3	3	3	2	3	2	3	3	2	3	-	3	3	3		-	-
CO2	3	3	3	3	2	3	2	3	3	2	3	-	3	3	3	-	-	-
CO3	3	3	3	3	3	3	3	3	3	2	3	-	3	3	3	-	-	-
CO4	3	3	3	3	2	3	3	3	3	3	3	-	3	3	3	-	-	-
CO5	3	3	3	3	2	3	3	3	3	3	3	-	3	3	3	-	-	-

1- Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator

Sign & Seal of HoD



Effective from session: 2016	-2017						
Course Code	MPH201T	Title of the Course	Molecular Pharmaceutics (Nanotechnology & Targeted DDS)	L	Т	Р	С
Year	Ι	Semester II					4
Pre-requisite	B Pharm	<b>Co-requisite</b>	_	4	-	-	4
Course Objective	2.The criteria	for selection of drugs a	pment of novel drug delivery systems. nd polymers for the development of NTDS novel drug delivery systems.			-	

	Course Outcomes
CO1	Recall the basic aspects and approaches of targeted drug delivery systems
CO2	Describe methods for the preparation and evaluation of polymeric nanoparticles and liposomes
CO3	Outline the preparation methods and applications of monoclonal antibodies and vesicular nanocarriers
CO4	Discuss the different aspects of pulmonary drug delivery systems
CO5	Choose components of nucleic acid based therapeutic delivery systems

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Targeted Drug Delivery Systems	Concepts, Events and biological process involved in drug targeting. Tumor targeting and Brain specific delivery.	12	1
2	Targeting Methods	Introduction, preparation and evaluation. Nanoparticles & Liposomes: Types, preparation and evaluation.	12	2
3	Microparticles, monoclonal antibodies and other carrier systems	Microcapsules/Microspheres: Types, preparation and evaluation Monoclonal Antibodies: Preparation and application Preparation and application of Niosomes, Aquasomes, Phytosomes, Electrosomes.	12	3
4	Pulmonary Drug Delivery Systems	Aerosols, propellants, Container Types, preparation and evaluation; Intra Nasal Route Delivery systems; Types, preparation and evaluation.	12	4
5	Nucleic acid based therapeutic delivery system	Gene therapy, introduction (ex-vivo & in-vivo gene therapy). Potential target diseases for gene therapy (inherited disorder and cancer). Gene expression systems (viral and nonviral gene transfer). Liposomal gene delivery systems. Biodistribution and Pharmacokinetics. knowledge of therapeutic antisense molecules and aptamers as drugs of future.	12	5

#### **Reference Books:**

1. Y W. Chien, Novel Drug Delivery Systems, 2nd edition, revised and expanded, Marcel Dekker, Inc., New York, 1992.

2. S.P.Vyas and R.K.Khar, Controlled Drug Delivery - concepts and advances, VallabhPrakashan, New Delhi, First edition 2002.

3. N.K. Jain, Controlled and Novel Drug Delivery, CBS Publishers & Distributors, NewDelhi, First edition 1997 (reprint in 2001).

4. Biopharmaceutics and Clinical Pharmacokinetics, An Introduction, 4<sup>th</sup> edition, revised and expande by Robert. E. Notari, Marcel Dekker Inc, New York and Basel, 1987.

5. Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick, James. G.Boylan, Marcel Dekker Inc, New York, 1996.

#### e-Learning Source:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571524/

			Cou	rse Arti	culatio	on Ma	trix: (1	Mappin	g of C	Os with	POs an	d PSOs)	)				
PO-P SO CO	PO1	PO 2	PO3	PO4	PO 5	PO 6	PO 7	PO8	PO9	PO10	PO11	PSO 1	PSO 2	PSO3	PSO4	PSO5	PSO6
CO1	3	3	3	3	3	3	2	3	3	2	3	3	3	3	-	-	-
CO2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	-	-	-
CO3	3	3	3	3	3	2	2	3	3	3	3	3	3	3	-	-	-
CO4	3	3	3	2	2	2	2	3	3	2	3	3	3	3	-	-	-
CO5	3	3	3	3	3	3	3	3	3	2	3	3	3	3	-	-	-

### 1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator



Effective from Session: 2016	5-2017											
Course Code	MPH-202T	Title of the Course	Advanced Biopharmaceutics & Pharmacokinetics	L	Т	Р	С					
Year	Ι	Semester II 4 0 0										
Pre-Requisite	B Pharm	Co-requisite	-	4	U	U	4					
Course Objectives	<ol> <li>2. The use of process of</li> <li>3. The critical</li> <li>4.The design biopharmac</li> </ol>	raw data and derive the drug absorption, distribu l evaluation of biopharn and evaluation of dosag ceutical parameters.	eutics and pharmacokinetics. pharmacokinetic models and parameters that best describe t ation, metabolism and elimination. haceutical studies involving drug product equivalency. e regimens of the drugs using pharmacokinetic and etic problems and application of basics of pharmacokinetics									

	Course Outcomes
CO1	Understand basic concepts in biopharmaceutics and pharmacokinetics.
CO2	Explain the design and evaluation of dosage regimens of the drugs using pharmacokinetic and biopharmaceutics parameters.
CO3	Analyze raw data and derive the pharmacokinetic models and parameters that best describes the process of drug absorption, distribution,
	metabolism and elimination.
CO4	Know critical evaluation of biopharmaceutics studies involving drug product equivalency.
CO5	Identify potential clinical pharmacokinetic problems and apply basic pharmacokinetic principles to solve them.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Drug Absorption from the Gastrointestinal Tract	Gastrointestinal tract, mechanism of drug absorption, factors affecting drug absorption, pH-partition theory of drug absorption. Formulation and physicochemical factors: Dissolution rate, dissolution process, Noyes- Whitney equation and drug dissolution, factors affecting the dissolution rate. Gastrointestinal absorption: role of the dosage form: Solution (elixir, syrup and solution) as a dosage form, suspension as a dosage form, capsule as a dosage form, tablet as a dosage form, dissolution methods, formulation and processing factors, correlation of in vivo data with in vitro dissolution data. Transport model: Permeability-solubility-charge state and the pH partition hypothesis, properties of the gastrointestinal tract (GIT), pH microclimate intracellular pH environment, tight-junction complex.	12	1
2	Biopharmaceutical Considerations in Drug Product Design and In Vitro Drug Product Performance	Introduction, biopharmaceutical factors affecting drug bioavailability, rate-limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance, in vitro: dissolution and drug release testing, compendial methods of dissolution, alternative methods of dissolution testing, meeting dissolution requirements, problems of variable control in dissolution testing, performance of drug products. In vitro–in vivo correlation, dissolution profile comparisons, drug product stability, considerations in the design of a drug product.	12	2
3	Pharmacokinetics	Basic considerations, pharmacokinetic models, compartment modeling: one compartment model- IV bolus, IV infusion, extra-vascular. Multi compartment model: two compartment - model in brief, non-linear pharmacokinetics: cause of non-linearity, Michaelis–Menten equation, estimation of Kmax and Vmax. Drug interactions: Introduction, the effect of protein binding interactions, the effect of tissue binding interactions, cytochrome p450-based drug interactions, and drug interactions linked to transporters.	12	3
4	Drug Product Performance, in vivo: Bioavailability and Bioequivalence:	Drug product performance, purpose of bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of bioequivalence studies, study designs, crossover study designs, evaluation of the data, bioequivalence example, study submission and drug review process. Biopharmaceutics classification system, methods. Permeability: In-vitro, in-situ and In-vivo methods. Generic biologics (biosimilar drug products), clinical significance of bioequivalence studies, special concerns in bioavailability and bioequivalence studies, generic substitution.	12	4
5	Application of Pharmacokinetics	Modified-release drug products, targeted drug delivery Systems and biotechnological products. Introduction to pharmacokinetics and pharmacodynamic, drug interactions. Pharmacokinetics and pharmacodynamics of biotechnology drugs. Introduction, proteins and peptides. Monoclonal antibodies, oligonucleotides, vaccines (immunotherapy), gene therapies.	12	5
	ence Books:			
	-	ical Pharmacokinetics by Milo Gibaldi, 4th edition, Philadelphia, Lea and Febiger, 1991.		
	*	rmacokinetics, A. Treatise, D. M. Brahmankar and Sunil B. Jaiswal., Vallabh Prakashan, Pitam		
		and Pharmacokinetics by Shargel. Land Yu ABC, 2ndedition, Connecticut Appleton Century C	rofts, 1985.	
		Gibaldi and D. Perrier, 2nd edition, Marcel Dekker Inc., New York, 1982		
	arning Source: s://fips.springeropen.com	/articles/10.1186/s43094-020-00047-9		

						C	ourse /	Articul	ation I	Matrix:	(Manni	ng of CO	s with PO	s and PS	()s)			
PO- PS	РО	РО	РО	РО	РО	PO	PO	PO	PO	PO1	PO1					Date 4		DG Q (
0 C0	1	2	3	4	5	6	7	8	9	0	1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO 2	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO 3	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO 4	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
CO 5	3	2	2	2	2	3	2	1	2	3	3	-	3	2	3	-	-	-
	1-				1-I	low Co	orrelati	ion; 2-	Mode	rate Cor	relation	ı; 3- Subs	stantial C	orrelation				

Name & Sign of Program Coordinator

Sign & Seal of HoD



Effective from Session: 2016	5-2017						
Course Code	MPH203T	Title of the Course	Computer Aided Drug Delivery System	L	Т	Р	С
Year	Ι	Semester	Π	1			4
Pre-Requisite	B Pharm	Co-requisite	-	4	-	-	4
Course Objectives	<ol> <li>Computation</li> <li>Computers</li> <li>Optimization</li> <li>Computers</li> <li>Computers</li> <li>Computers</li> <li>Artificial In</li> </ol>	Computers in Pharmacet onal Modeling of Drug I in Preclinical Developm on Techniques in Pharm in Market Analysis in Clinical Developmen ntelligence (AI) and Rol onal fluid dynamics(CFI	nent aceutical Formulation nt potics				

	Course Outcomes
CO1	Describe statistical modeling and quality by design in pharmaceutical research and development
CO2	Discuss the descriptors of drug disposition utilized in computational modeling
CO3	Understand the ethics and legal protection of computing in pharmaceutical research
CO4	Defend in silico approaches for biopharmaceutical characterization
CO5	Recognize the importance of automation in pharmaceutical development

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Computers and Quality-by-Design in pharmaceutical research and development	Computers in pharmaceutical research and development: History of computers in pharmaceutical research and development, introduction of statistical modeling in pharmaceutical research and development, different statistical models in pharmaceutical research and development, descriptive versus mechanistic modeling, statistical parameter, estimation, confidence regions, nonlinearity at the optimum, sensitivity analysis, optimal design, population modeling Quality-by-Design in pharmaceutical development: Introduction, concept and components of QbD, ICH Q8 guideline, regulatory and industry views on QbD, scientifically based QbD-examples of application	12	1
2	Computational modeling of drug disposition	Introduction, modeling techniques, drug absorption, solubility, intestinal permeation, drug distribution, drug excretion, active transport, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), nucleoside transporters, human peptide transporter (hPEPT1), apical sodium dependent bile acid transporter (ASBT), organic cation transporter (OCT), organic anion transporting polypeptide (OATP), blood brain barrier-choline transporter	12	2
3	Computer-aided formulation development	Concept of optimization, optimization parameters, factorial design, optimization technology and screening design. Computers in pharmaceutical formulation: development of pharmaceutical emulsions, development of microemulsion drug carriers. Legal protection of innovative uses of computers in research and development, The ethics of computing in pharmaceutical research, computers in market analysis	12	3
4	Computer-aided biopharmaceutical and clinical characterization	Computer-aided biopharmaceutical characterization: Theoretical background of gastrointestinal absorption simulation, model construction, parameter sensitivity analysis, virtual trial, fed vs. fasted state, <i>in vitro</i> dissolution and <i>in vitro-in vivo</i> correlation, biowaiver considerations. Computer simulations in pharmacokinetics and pharmacodynamics: Introduction, computer simulation: whole organism, isolated tissues, organs, cell, proteins and genes. Computers in clinical development: Introduction, clinical data collection and management, regulation of computer systems.	12	4
5	Artificial intelligence, robotics and computational fluid dynamics	General overview, pharmaceutical automation, pharmaceutical applications, advantages and disadvantages, current challenges and future directions	12	5
	ice Books:			
. Comp	outer Applications in Pha	armaceutical Research and Development, Sean Ekins, 2006, John Wiley & Sons.		

1. Computer Applications in Pharmaceutical Research and Development, Sean Ekins, 2006, John Wiley & Sons.

2. Computer-Aided Applications in Pharmaceutical Technology, 1st Edition, Jelena Djuris, Woodhead Publishing

Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick, James. G.Boylan, Marcel Dekker Inc, New York, 1996.
 Basic Pharmacokinetics, 1 st edition, Sunil S JambhekarandPhilip J Breen, pharmaceutical press, RPS Publishing, 2009.
 Applied Biopharmaceutics and Pharmacokinetics by Shargel. Land YuABC, 2ndedition, Connecticut Appleton Century Crofts, 1985.

e-Learning Source:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248982/

				Cou	rse Ar	ticulatio	on Ma	trix: (N	lappir	ng of CO	Os with	POs and	I PSC	Ds)				
PO-PS O CO	PO1	PO2	PO3	PO4	PO 5	PO6	PO 7	PO8	PO 9	PO1 0	PO11	PO12	PS O 1	PS O2	PS O3	PS O4	PS O5	PD O6
CO1	3	3	3	3	3	3	2	3	3	2	3	-	3	3	3	-	-	-
CO2	3	3	3	3	3	3	3	3	3	3	3	-	3	2	3	-	—	-
CO3	3	3	3	3	3	3	3	3	3	3	3	-	3	3	3	-	-	-
CO4	3	3	3	3	2	2	2	3	3	2	3	-	3	3	3	-	-	-
CO5	3	3	3	3	2	3	3	3	3	2	3	-	3	3	2	-	-	-

### 1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2016	-2017											
Course Code	MPH204T	<b>Title of the Course</b>	Cosmetics and Cosmeceuticals	L	Т	Р	С					
Year	Ι	Semester	II			0						
Pre-Requisite												
Course Objectives	<ol> <li>Key buildin</li> <li>Current tec</li> <li>Various key</li> </ol>		rmulations.	nd effi	cacy.							

	Course Outcomes
CO1	Gain information on key ingredients used in cosmetics and cosmeceuticals
CO2	Understand key building blocks of cosmetics for various formulations
CO3	Know the current technologies in the market
CO4	Understand the scientific principles to develop cosmetics and cosmeceuticals with desired safety
CO5	Understand the regulatory aspects in cosmetics

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Cosmetics: Regulatory	Definition of cosmetic products as per Indian regulation. Indian regulatory requirements for labeling of cosmetics Regulatory provisions relating to import of cosmetics. Misbranded and spurious cosmetics. Regulatory provisions relating to manufacture of cosmetics – Conditions for obtaining license, prohibition of manufacture and sale of certain cosmetics, loan license, offences and penalties.	12	1, 5
2	Cosmetics : Biological aspects	Structure of skin relating to problems like dry skin, acne, pigmentation, prickly heat, wrinkles and body odor. Structure of hair and hair growth cycle. Common problems associated with oral cavity. Cleansing and care needs for face, eye lids, lips, hands, feet, nail, scalp, neck, body and under-arm.	12	2,4
3	Formulation: Building blocks	Building blocks for different product formulations of cosmetics/cosmeceuticals. Surfactants -Classification and application. Emollients, rheological additives: classification and application. Antimicrobial used as preservatives, their merits and demerits. Factors affecting microbial preservative efficacy. Building blocks for formulation of a moisturizing cream, vanishing cream, cold cream, shampoo and toothpaste. Soaps and syndetbars. Perfumes; Classification of perfumes. Perfume ingredients listed as allergens in EU regulation. Controversial ingredients: Parabens, formaldehyde liberators, dioxane.	12	1, 2, 5
4	Design of cosmeceutical products	Sun protection, sunscreens classification and regulatory aspects. Addressing dry skin, acne, sun-protection, pigmentation, prickly heat, wrinkles, body odor, dandruff, dental cavities, bleeding gums, mouth odor and sensitive teeth through cosmeceutical formulations.	12	1, 2, 4
5	Herbal Cosmetics	Herbal ingredients used in Hair care, skin care and oral care. Review of guidelines for herbal cosmetics by private bodies like cosmos with respect to preservatives, emollients, foaming agents, emulsifiers and rheology modifiers. Challenges in formulating herbal cosmetics.	12	1, 3, 4, 5
Reference	ce Books:			
1. Ha	arry's Cosmeticology. 8	th edition.		
2. Co	osmetics - Formulation,	Manufacture and quality control, PP.Sharma, 4th edition		
3. Ha	andbook of cosmetic sc	ience and Technology A.O.Barel, M.Paye and H.I. Maibach. 3 rd edition		
4. Co	osmetic and Toiletries re	ecent suppliers catalogue.		
e-Lear	ning Source:			
1. US	SFDA: <u>https://www.f</u>	da.gov/cosmetics		
2. CI	DSCO: <u>https://cdsco.g</u>	ov.in/opencms/opencms/en/Cosmetics/cosmetics/		

						С	ourse A	Articul	ation I	Matrix:	(Mappi	ng of CO	s with PC	s and PS	Os)			
PO- PS 0 CO	PO 1	PO 2	PO 3	PO 4	PO 5	PO 6	PO 7	РО 8	PO 9	PO1 0	PO1 1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	1	1	-	-	-	3	-	-	2	1	1	-	2	1	1	-	-	-
CO 2	1	1	-	-	-	3	-	-	2	1	1	-	2	1	1	-	-	-
CO 3	1	1	-	-	-	3	-	-	2	1	1	-	3	1	1	-	-	-

CO 4	1	1	-	-	-	3	-	-	2	1	1	-	3	1	1	-	-	-
CO 5	1	1	-	-	-	3	-	-	2	1	1	-	3	1	1	-	-	-
	1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation																	

Name & Sign of Program Coordinator

Sign & Seal of HoD



Effective from Session:2016	-2017											
-Course Code	MPH205P	Title of the Course	Pharmaceutics Practical-II	L	Т	Р	С					
Year	Ι	Semester	II			10						
Pre-Requisite	B Pharm	Co-requisite	12									
Course Objectives	2.Key buildin 3.Current tecl 4.Various key		mulations.	d effic	acy.							

	Course Outcomes
CO1	Develop and evaluate different novel formulations by suitable methods.
CO2	Design and optimize formulations by using Design of Experiment approach.
CO3	Solve problems related to protein binding and bioavailability studies.
CO4	Apply in silico approach for simulations of pharmacokinetics and pharmacodynamics.
CO5	Use scientific knowledge to develop and evaluate cosmetic formulations

Exper iment No.	Title of the Experiment	Content of Unit	Contact Hrs.	Mapped CO
1	Microcapsules	To study the effect of temperature change, non solvent addition, in compatible polymer addition in microcapsules prepararion.	12	1
2	Beads	To prepare and evaluate alginate beads.	12	1
3	Microspheres	Formulation and evaluation of liposomes/niosomes,spherules.	12	1
4	Solid dispersion	Improvement of dissolution characteristic of slightly soluble drug by solid dispersion.	12	1
5	Dissolution characters	Comparison of dissolution of different marketed products.	12	1
6	Protein binding	To study protein binding of highly protein bound drug & poorly protein bound drug.	12	3
7	Bioavailability	To study the bioavailability of given drug.	12	3
8	Pharmacokinetic analysis	Pharmacokineticand IVIVC data analysis by Winnoline software.	12	4
9	Permeability	In vitro cell study for permeability and metabolism.	12	4
10	DOE	Design Expert software, formulation data analysis and Quality-by-design in Pharmaceutical Development	12	2
11	Computer Simulation	Computer Simulation in Pharmacokinetics & Pharmacodynamics.	12	2,4
12	Computational Modeling	Computational Modeling of Drug Disposition.	12	2
13	Clinical Data	To develop Clinical Data manual.	12	2
14	Modeling	To carry out Sensitivity Analysis, and Population Modeling.	12	2
15	Cosmeceuticals	Development & evaluation of creams, Shampoo & Toothpaste and incorporation of herbal & chemical actives to develop products.	12	5
Refere	ence Books:			

Handbook of cosmetic science and Technology A.O.Barel, M.Paye and H.I. Maibach. 3 rd edition

Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick, James. G.Boylan, Marcel Dekker Inc, New York, 1996.

Biopharmaceutics and Relevant Pharmacokinetics by John. G Wagner and M.Pemarowski, 1st edition, Drug Intelligence Publications, Hamilton, Illinois, 1971.

e-Learning Source:

https://www.pharmatutor.org/articles/details-on-formulation-and-evaluation-of-microspheres

https://www.scielo.br/j/bjps/a/zwwMpgN95HsPkzTG9B5FpWg/?format=pdf

https://www.researchgate.net/publication/325023106

		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO-P SO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO1 0	PO1 1	PO1 2	PSO1	PSO2	PS O3	PS O4	PS O5	PS O6
CO1	3	3	3	3	3	3	2	3	3	3	3	-	3	3	3	-	-	-
CO2	3	3	3	3	3	3	3	3	3	3	3	-	3	3	3	-	-	-



CO3	3	3	3	3	3	3	3	3	3	2	3	-	3	2	3	-	-	-
CO4	3	3	3	3	3	2	3	3	3	2	3	-	3	3	3	-	-	-
CO5	3	3	3	3	2	2	3	3	3	3	3	-	2	3	2	-	-	-

1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2017-2018											
Course Code	MRM 301 T	Title of the Course	Research Methodology & Biostatistics	L	Т	Р	С				
Year	Π	Semester	III	4	0		4				
Pre-Requisite		Co-requisite		4	0	0	4				
Course Objectives	2. I 3. H 4. H	Demonstrate the types Explain the CPCSEA Explain the different e	irements for designing the research project. of statistical methods. guidelines for keeping the laboratory animals. ethical principles for conducting the clinical trials. declaration of Helsinki and ICG guidelines								

		Course Outcomes
C	01	After studying this subject, students will learn regarding the strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.
C	02	Students can demonstrate different statistical methods for calculation of data such as t test, ANOVA, wilcoxan rank tests etc.
C	03	Students will learn about history, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality etc.
C	04	After studying this subject, students can explain the CPCSEA guidelines for laboratory animal facility.
C	05	After studying this subject, students will know the Declaration of Helsinki: History, introduction, basic principles for all medical
		research,

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	General Research Methodology:	Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.	12	3
2	Biostatistics:	Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, type of significance tests, parametric tests(students "t" test, ANOVA, Correlation coefficient, regression), non-parametric tests (wilcoxan rank tests, analysis of variance, correlation, chi square test), null hypothesis, P values, degree of freedom, interpretation of P values.	12	3
3	Medical Research:	History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality.	12	3
4	CPCSEA guidelines for laboratory animal facility:	CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.	12	2

5	Declaration of Helsinki:	Helsinki:       History, introduction, basic principles for all medical research, and additional principles for medical research combined with medical care.									
Referen	nce Books:		•								
Del	lhi: Ministry of Health;2001										
	2. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996.										
3.Ethica	al Guidelines for Biomedica	Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.									
4.Textbo	ook of Clinical Trials edited	by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.									
e-Lea	rning Source:										
<u>https:</u>	//drive.google.com/drive/fo	<u> blders/1W4b4NRhqBQWMC14vsBNZcdc2LWFFmcrd?usp=share_link</u>									

						Cou	rse Ar	ticulati	on Ma	trix: (M	apping o	of COs w	ith POs a	nd PSOs	)		_	
PO- PS O CO	РО 1	PO 2	PO 3	PO 4	PO 5	PO 6	<b>PO</b> 7	PO 8	PO 9	PO1 0	PO1 1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	2	3	3	3	3	3	3	2	3	3	3	-	3	2	3	-	-	
CO 2	3	3	3	3	3	2	2	3	2	2	2	-	2	3	3	-	-	
CO 3	3	2	2	2	2	2	3	1	3	3	3	-	3	3	3	-	-	
CO 4	3	3	3	3	3	2	2	2	3	2	2	-	3	3	3	-	-	
CO 5	3	2	3	3	1	1	3	1	2	3	3	-	2	2	3	-	-	

1-

Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator

Sign & Seal of HoD